Prospect for an additional laboratory criterion for rheumatoid arthritis
- PMID: 7505480
- DOI: 10.3109/03009749309095137
Prospect for an additional laboratory criterion for rheumatoid arthritis
Abstract
The aim of the study was to establish the benefit of an additional hypothetical laboratory criterion for rheumatoid arthritis (RA), comprising positivity for antikeratin antibody (AKA) and/or antiperinuclear factor (APF). The tests were applied to a series of 308 hospital patients with various recent-onset inflammatory joint diseases who were followed for 3 years. The performance of APF and AKA was compared with rheumatoid factor (RF). The most sensitive (.72) but the least specific (.86) test for RA was the latex test. The most specific (.96) but the least sensitive (.33) test was AKA. Waaler-Rose and APF were intermediate. AKA and/or APF positive patients had significantly more erosions than patients negative for these autoantibodies. Despite the impressive performance characteristics of APF and AKA, the actual classification impact achieved, as compared to using RF as the sole laboratory criterion, turned out to be moderate. This is because the criteria proved to be interrelated. Unlike RF, AKA and APF are not suited to the general laboratory, at least not in their present form. Moreover they so far lack the broad data base of RF.
Similar articles
-
Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor.Br J Rheumatol. 1996 Jul;35(7):620-4. doi: 10.1093/rheumatology/35.7.620. Br J Rheumatol. 1996. PMID: 8670593
-
Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process.J Rheumatol. 1993 Aug;20(8):1278-81. J Rheumatol. 1993. PMID: 7693940
-
Rheumatoid factors, anti-filaggrin antibodies and low in vitro interleukin-2 and interferon-gamma production are useful immunological markers for early diagnosis of community cases of rheumatoid arthritis. A preliminary study.Joint Bone Spine. 2001 Mar;68(2):144-53. doi: 10.1016/s1297-319x(00)00244-x. Joint Bone Spine. 2001. PMID: 11324930 Clinical Trial.
-
The antiperinuclear factor and antikeratin antibody systems.Int Arch Allergy Immunol. 1995 Aug;107(4):508-18. doi: 10.1159/000237093. Int Arch Allergy Immunol. 1995. PMID: 7542514 Review.
-
Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications.Semin Arthritis Rheum. 1994 Jun;23(6):379-87. doi: 10.1016/0049-0172(94)90088-4. Semin Arthritis Rheum. 1994. PMID: 7524151 Review.
Cited by
-
Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis.Ann Rheum Dis. 2001 Sep;60(9):882-7. Ann Rheum Dis. 2001. PMID: 11502616 Free PMC article.
-
Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides.Ann Rheum Dis. 1999 Jan;58(1):42-8. doi: 10.1136/ard.58.1.42. Ann Rheum Dis. 1999. PMID: 10343539 Free PMC article. Clinical Trial.
-
Antikeratin antibodies (AKA) negativity in primary biliary cirrhosis (PBC): confirmation of their specificity in the diagnosis of rheumatoid arthritis (RA).Clin Rheumatol. 1996 Nov;15(6):617-8. doi: 10.1007/BF02238555. Clin Rheumatol. 1996. PMID: 8973875 No abstract available.
-
Anti-perinuclear Factor as Diagnostic Marker in Rheumatoid Arthritis.J Clin Diagn Res. 2015 Sep;9(9):OC13-6. doi: 10.7860/JCDR/2015/14962.6456. Epub 2015 Sep 1. J Clin Diagn Res. 2015. PMID: 26500935 Free PMC article.
-
Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study.Clin Rev Allergy Immunol. 2008 Feb;34(1):40-4. doi: 10.1007/s12016-008-8073-2. Clin Rev Allergy Immunol. 2008. PMID: 18247159
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical